Table 3.
Univariate analysis of poor prognostic factors for OS, DFS, LRFS, and DMFS in OSCC patients.
| OS | DFS | LRFS | DMFS | |||||
| Variable | HR (95% CI) | p -Value | HR (95% CI) | p -Value | HR (95% CI) | p -Value | HR (95% CI) | p -Value |
| Age (years) | ||||||||
| <65 | Reference | Reference | Reference | Reference | ||||
| ≥65 | 1.622 | <0.001 * | 1.454 | 0.001 * | 1.459 | 0.001 * | 1.597 | <0.001 * |
| (1.275–2.064) | (1.149–1.839) | (1.154–1.846) | (1.254–2.035) | |||||
| Gender | ||||||||
| Female | Reference | Reference | Reference | Reference | ||||
| Male | 0.833 | 0.275 | 0.773 | 0.102 | 0.773 | 0.102 | 0.832 | 0.269 |
| (0.601–1.156) | (0.567–1.053) | (0.567–1.053) | (0.599–1.154) | |||||
| Overall Stage | ||||||||
| I–II | Reference | Reference | Reference | Reference | ||||
| III–IV | 2.614 | <0.001 * | 2.287 | <0.001 * | 2.282 | <0.001 * | 2.610 | <0.001 * |
| (2.084–3.279) | (1.852–2.824) | (1.848–2.818) | (2.080–3.274) | |||||
| Surgical margin | ||||||||
| <5 mm | Reference | Reference | Reference | Reference | ||||
| ≥5 mm | 1.352 | 0.005 * | 1.282 | 0.016 * | 1.279 | 0.017 * | 1.353 | 0.004 * |
| (1.096–1.668) | (1.047–1.571) | (1.045–1.567) | (1.096–1.670) | |||||
| ENE | ||||||||
| Absent | Reference | Reference | Reference | Reference | ||||
| Present | 3.072 | <0.001 * | 2.865 | <0.001 * | 2.853 | <0.001 * | 3.096 | <0.001 * |
| (2.471–3.819) | (2.318–3.540) | (2.309–3.526) | (2.490–3.850) | |||||
| Cell differentiation | ||||||||
| W-D/M-D | Reference | Reference | Reference | Reference | ||||
| P-D | 1.746 | <0.001 * | 1.745 | <0.001 * | 1.751 | <0.001 * | 1.758 | <0.001 * |
| (1.323–2.305) | (1.337–2.277) | (1.341–2.285) | (1.331–2.320) | |||||
| LVI | ||||||||
| Absent | Reference | Reference | Reference | Reference | ||||
| Present | 1.721 | 0.001 * | 1.631 | 0.003 * | 1.608 | 0.004 * | 1.731 | 0.001 * |
| (1.231–2.406) | (1.177–2.260) | (1.161–2.228) | (1.238–2.420) | |||||
| PNI | ||||||||
| Absent | Reference | Reference | Reference | Reference | ||||
| Present | 1.871 | <0.001 * | 1.718 | <0.001 * | 1.716 | <0.001 * | 1.860 | <0.001 * |
| (1.530–2.289) | (1.415–2.084) | (1.414–2.082) | (1.520–2.275) | |||||
| DOI | ||||||||
| <10 mm | Reference | Reference | Reference | Reference | ||||
| ≥10 mm | 2.309 | <0.001 * | 2.047 | <0.001 * | 2.041 | <0.001 * | 2.303 | <0.001 * |
| (1.877–2.841) | (1.682–2.490) | (1.678–2.484) | (1.871–2.834) | |||||
| Adjuvant Tx | ||||||||
| Without | Reference | Reference | Reference | Reference | ||||
| With | 2.326 | <0.001 * | 2.199 | <0.001 * | 2.195 | <0.001 * | 2.321 | <0.001 * |
| (1.868–2.896) | (1.787–2.706) | (1.784–2.701) | (1.864–2.890) | |||||
| PIV | ||||||||
| <268 | Reference | Reference | Reference | Reference | ||||
| ≥268 | 1.723 | <0.001 * | 1.531 | <0.001 * | 1.521 | <0.001 * | 1.717 | <0.001 * |
| (1.410–2.105) | (1.264–1.854) | (1.255–1.842) | (1.405–2.099) | |||||
Abbreviations: OS: overall survival; DFS: disease-free survival; LRFS: locoregional recurrence-free survival; DMFS: distance metastasis-free survival; HR: hazard ratio; CI: confidence interval; ENE, extranodal extension; W-D: well-differentiated, M-D: moderately differentiated, and P-D: poorly differentiated; LVI, lymphovascular invasion; PNI, perineural invasion; DOI, depth of invasion; Adjuvant tx: radiotherapy or chemoradiotherapy; PIV: pan-immune-inflammation value; * Statistically significant.